Episode 391: Tomorrow's Breakthroughs Depend on Today's Research Investments

There is a lot of conversation right now about funding for cancer research and possible cuts to research projects that will improve our understanding and treatment of breast cancer. I’m pleased to be joined today by two researchers who are sharing their perspectives on the inextricable link between grant funding and sustained research.  Dr. Benjamin Schrank is an Assistant Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and Dr. Donald McDonnell is the Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology at Duke University School of Medicine. Dr. McDonnell is a well-established researcher whose work focuses on developing new drugs to treat metastatic breast cancer.  Dr. Schrank is early in his research career and focused on harnessing the body’s immune system to improve response to treatments for metastatic breast cancer. Both recently received research grants from Susan G. Komen to support their innovative work that will help improve breast cancer care and patient outcomes. Key Takeaways: Breakthrough cancer treatments can take decades to develop Fundamental research is the foundation of future therapies Early-stage funding is critical for innovation Research funding directly impacts patients Chapters 00:00 Introduction 01:40 Meet the researchers and their current projects 03:45 Why medical breakthroughs take decades to achieve 11:15 The critical role of grant funding in scientific research 20:20 Supporting the next generation of cancer researchers Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.